The LN-229 cell line was established in 1979 from cells taken from a patient with right frontal parieto-occipital glioblastoma [PubMed. 10416987].
p53 + (mutated, CCT (Pro) --> CTT (Leu) mutation at codon 98), PTEN + (wild type), p16 - (deleted), p14ARF - (deleted)
Forms tumors in nude mice
Used in allogeneic xenografts
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA.
Because we specialize in tumor models, we're able to offer highly competitive prices.
Most efficacy studies can be initiated within two business days.